World Journal of Gastroenterology · 2019 · 27 citations · 7 references
PharmacyInfectious DiseasesPharmacotherapyHepatologyMolecular VirologyVirologyAntiviral TherapyInterferon-based TherapyLiver DiseaseViral HepatitisViral Hepatitis TreatmentViral Rna BiologyChronic Viral HepatitisEntecavir TherapyHbv Dna SuppressionHepatitis B TherapySeroconversion DetectionSeroconversion RatesVirological Diagnosis
BACKGROUND: Characteristics of alterations of serum hepatitis B virus (HBV) RNA in different chronic hepatitis B (CHB) patients still cannot be fully explained. Whether HBV RNA can predict HBeAg seroconversion is still controversial. AIM: To investigate whether HBV RNA can predict virological response or HBeAg seroconversion during entecavir (ETV) treatment when HBV DNA is undetectable. METHODS: The present study evaluated 61 individuals who were diagnosed and treated with long-term ETV monotherapy at the Department of Infectious Diseases of Peking University First Hospital (China) from September 2006 to December 2007. Finally, 30 treatment-naive individuals were included. Serum HBV RNA were extracted from 140 μL serum samples at two time points. Then they were reverse transcribed to cDNA with the HBV-specific primer. The product was quantified by real-time quantitative PCR (RT-PCR) using TAMARA probes. Statistical analyses were performed with IBM SPSS 20.0. RESULTS: copies/mL before treatment. CONLUSION: The level of serum HBV RNA could predict HBeAg seroconversion and PVR during treatment. In the PVR group, the level of serum HBV RNA tends to be increasing.
7
L. Jansen, Neeltje A. Kootstra, Karel A. van Dort et al. · The Journal of Infectious Diseases · 2015 · 152 citations · Full text